Generic names: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection, Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine Solution for intramuscular injection
Indication and Usage:
Menactra is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra is approved for use in individuals 9 months through 55 years of age. Menactra does not prevent N meningitidis serogroup B disease.
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.
Menactra is a sterile, intramuscularly administered vaccine that contains N meningitidis serogroup 8 A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid 9 protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar and 10 grown in Watson Scherp media containing casamino acid. Each 0.5 mL dose may contain residual 20 amounts of formaldehyde of less than 2.66 mcg (0.000532%), by calculation.
Manufacturer-listed adverse reactions |
Menactra can cause: Lymphadenopathy, Anaphylaxis/anaphylactic reaction, Wheezing, Difficulty breathing, Upper airway swelling, Urticaria (Hives), Erythema, Pruritus, Hypotension, Guillain-Barré syndrome, Paraesthesia, Vasovagal syncope, Dizziness, Convulsion, Facial palsy, Acute disseminated encephalomyelitis, Transverse myelitis, Myalgia, Large injection site reactions, extensive swelling of the injected limb (may be associated with erythema, warmth, tenderness or pain at the injection site).
Menveo can cause: Local lymphadenopathy, Hearing impaired, Ear pain, Vertigo, Vestibular disorder, Eyelid ptosis, Injection site pruritus, Pain, Erythema, Inflammation/swelling, including extensive swelling of the vaccinated limb, Fatigue, Tonic convulsion, Headache, Facial paresis, Balance disorder, Malaise (Discomfort), Pyrexia, Hypersensitivity reactions, Anaphylaxis, Vaccination site cellulitis, Fall, head injury, Alanine aminotransferase increased, Body temperature increased, Arthralgia, Bone pain, Dizziness, Syncope, Oropharyngeal pain, Skin exfoliation, Bell’s palsy.
Limitations of Effectiveness: Menactra may not protect all recipients.
Need more info? Click the link below for a helpful infographic you can view + save on your device.